Border

Major Biotech Deal Alert

Border

AbbVie has agreed to acquire Apogee Therapeutics in a $10.9 billion deal, strengthening its position in the fast-growing immunology market.

The acquisition brings zumilokibart, a promising late-stage treatment for eczema (atopic dermatitis), into AbbVie’s portfolio. Industry experts believe the therapy could offer a competitive alternative to existing treatments with the potential for less frequent dosing and improved patient convenience.

This move highlights the continued race among pharmaceutical companies to develop innovative therapies for chronic inflammatory diseases and improve outcomes for millions of patients worldwide.

What impact do you think this acquisition will have on the future of eczema treatment?

Click here to read the entire article.

Did you find this helpful? Share with your network!

More Tips From The Bandish Group

Border Line

The Skills Employees Need to Succeed in the Age of AI

◆

Artificial intelligence is changing the workplace, but the skills employees need in the age of AI are not necessarily new.…

#455: Interview Questions for Hiring Managers: How to Identify the Right Candidate

◆

An effective interview is about more than confirming what’s already listed on a candidate’s resume. It’s an opportunity for hiring…

Scroll to Top